Ashley Chan

Ashley Chan joined the OncLive team as an assistant editor in 2025 after previously working on the CURE editorial team since 2023.

Email: achan@mjhlifesciences.com

Articles

Immunotherapy Agents and ADCs May Redefine Early-Stage TNBC Management

May 18th 2025

Alexis LeVee, MD, discusses treatment challenges associated with TNBC and ongoing trials that may improve outcomes for patients with early-stage disease.

Zanidatamab/Chemotherapy Yields Responses and Is Safe in HER2-Expressing Metastatic Breast Cancer

May 16th 2025

Zanidatamab/chemotherapy showed early antitumor activity with a manageable safety profile in patients with HER2-expressing metastatic breast cancer.

Iza-Bren Shows Preliminary Efficacy, Safety in Heavily Pretreated HER2–/HER2-low Breast Cancer

May 16th 2025

Iza-bren was safe and displayed early clinical activity in patients with heavily pretreated breast cancer across both HER2-low and HER2-negative subgroups.

Ribociclib/Endocrine Therapy Yields Similar pCRs Compared With Chemotherapy in HR+ Early Breast Cancer

May 15th 2025

Neoadjuvant data from the ADAPTcycle trial confirmed the limited benefit of chemotherapy over endocrine therapy in high-risk HR-positive breast cancer.

Emiltatug Ledadotin Shows Early Clinical Activity and Safety in Advanced/Metastatic TNBC

May 15th 2025

Emiltatug Ledadotin generated initial responses and was tolerable in heavily pretreated patients with advanced/metastatic TNBC.

Dr Janjigian on Future Research Directions for Immunotherapy in Gastric/GEJ/Esophageal Cancer

May 15th 2025

Yelena Y. Janjigian, MD, discusses future research directions with nivolumab-based treatments in gastric, GEJ, and esophageal cancer.

Lung Cancer Experts Highlight the Most Anticipated Abstracts at the 2025 ASCO Annual Meeting

May 15th 2025

Ahead of the 2025 ASCO Annual Meeting, lung cancer experts highlight the abstracts and related trials they’re looking forward to seeing at the meeting.

Dr Beckermann on the Rationale for Evaluating Tivozanib/Nivolumab After IO-Based Therapy in RCC

May 14th 2025

Kathryn E. Beckerman, MD, PhD, details the rationale for evaluating tivozanib/nivolumab following immune checkpoint inhibitors in renal cell carcinoma.

Sitravatinib/Nivolumab Shows Modest Activity in Progressive Metastatic Clear Cell RCC Before Trial Termination

May 14th 2025

Sitravatinib plus nivolumab did not produce significant antitumor activity or survival outcomes in patients with progressive metastatic clear cell RCC.

Rhenium (Re186) Obisbemeda Shows Initial Safety, Clinical Benefit in Leptomeningeal Metastases

May 14th 2025

The novel injectable radiotherapy 186RNL showed safety and clinical activity as treatment for patients with leptomeningeal metastases.

AlloNK Plus Rituximab Induces Durable Responses in R/R B-Cell NHL

May 14th 2025

Longer-term phase 1/2 data with AB-101 plus rituximab showed high, durable responses in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

Dr Schmidt on the Development of Novel Treatment Delivery Approaches in Bladder Cancer

May 13th 2025

Bogdana Schmidt, MD, MPH, details the emergence of novel treatment delivery methods in bladder cancer.

BCG Shortage Warrants Treatment Shifts, New Treatment Strategies in Bladder Cancer

May 13th 2025

Bogdana Schmidt, MD, MPH, details the role of BCG in bladder cancer and navigating BCG shortages across the board during Bladder Cancer Awareness Month.

Capecitabine/Bevacizumab Yields Antitumor Activity and a Favorable Safety Profile in Older mCRC Population

May 13th 2025

Capecitabine/bevacizumab had favorable efficacy and safety profiles among older patients with metastatic colorectal cancer.

Large Clonal Hematopoiesis Clones Are Associated With Worse Survival Outcomes in MCL

May 13th 2025

Patients with MCL and large clonal hematopoiesis clones experienced shortened PFS and OS vs those without clones.

Dr Jahan on the Role of T-DXd in HR+/HER2-Low Metastatic Breast Cancer

May 12th 2025

Nusrat Jahan, MD, explains the role of T-DXd as the first cytotoxic therapy in patients with HR-positive/HER2-low or -ultralow breast cancer.

Belzutifan Displays Robust Activity in VHL-Associated RCC

May 12th 2025

Belzutifan was safe and effective in patients with von Hippel-Lindau–associated RCC and other neoplasms.

Bendamustine/Rituximab Represents a Backbone for Therapeutic Development in MCL

May 10th 2025

Brad S. Kahl, MD, details the evaluation of induction BR plus bortezomib with rituximab/lenalidomide maintenance in mantle cell lymphoma.

SOC Encorafenib/Binimetinib Sets a Precedent for Therapeutic Improvements in BRAF V600E–Mutant NSCLC

May 9th 2025

Joseph C. Murray, MD, highlights positive treatment shifts that have shaped the BRAF V600E–mutant non–small cell lung cancer treatment paradigm.

Adavosertib Shows Early Antitumor Activity Despite Safety Concerns in Uterine Serous Carcinoma

May 8th 2025

Adavosertib monotherapy demonstrated signs of antitumor activity in uterine serous carcinoma; however, the phase 2 starting dose was not well tolerated.